These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12571411)

  • 1. Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine.
    Jain NK; Patil CS; Singh A; Kulkarni SK
    Pharmacology; 2003 Mar; 67(3):150-6. PubMed ID: 12571411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception.
    Patil CS; Jain NK; Singh VP; Kulkarni SK
    Indian J Exp Biol; 2004 Apr; 42(4):361-7. PubMed ID: 15088685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway.
    Jain NK; Patil CS; Singh A; Kulkarni SK
    Brain Res; 2001 Aug; 909(1-2):170-8. PubMed ID: 11478933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulatory effect of cyclooxygenase inhibitors on sildenafil-induced antinociception.
    Patil CS; Jain NK; Singh A; Kulkarni SK
    Pharmacology; 2003 Dec; 69(4):183-9. PubMed ID: 14624058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil produces antinociception and increases morphine antinociception in the formalin test.
    Mixcoatl-Zecuatl T; Aguirre-Bañuelos P; Granados-Soto V
    Eur J Pharmacol; 2000 Jul; 400(1):81-7. PubMed ID: 10913588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of diabetes on the mechanisms of intrathecal antinociception of sildenafil in rats.
    Araiza-Saldaña CI; Reyes-García G; Bermúdez-Ocaña DY; Pérez-Severiano F; Granados-Soto V
    Eur J Pharmacol; 2005 Dec; 527(1-3):60-70. PubMed ID: 16305795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecally injected morphine inhibits inflammatory paw edema: the involvement of nitric oxide and cyclic-guanosine monophosphate.
    Brock SC; Tonussi CR
    Anesth Analg; 2008 Mar; 106(3):965-71, table of contents. PubMed ID: 18292447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway.
    Duarte ID; Ferreira SH
    Mediators Inflamm; 2000; 9(1):25-30. PubMed ID: 10877451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway.
    Riazi K; Roshanpour M; Rafiei-Tabatabaei N; Homayoun H; Ebrahimi F; Dehpour AR
    Br J Pharmacol; 2006 Apr; 147(8):935-43. PubMed ID: 16474413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sildenafil increases diclofenac antinociception in the formalin test.
    Asomoza-Espinosa R; Alonso-López R; Mixcoatl-Zecuatl T; Aguirre-Bañuelos P; Torres-López JE; Granados-Soto V
    Eur J Pharmacol; 2001 Apr; 418(3):195-200. PubMed ID: 11343689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of L-arginine/NO/cGMP/K(ATP) channel pathway in the peripheral antinociceptive actions of ellagic acid in the rat formalin test.
    Ghorbanzadeh B; Mansouri MT; Hemmati AA; Naghizadeh B; Mard SA; Rezaie A
    Pharmacol Biochem Behav; 2014 Nov; 126():116-21. PubMed ID: 25278343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive antinociception between intrathecal sildenafil and morphine in the rat formalin test.
    Yoon MH; Park KD; Lee HG; Kim WM; An TH; Kim YO; Huang LJ; Hua CJ
    J Korean Med Sci; 2008 Dec; 23(6):1033-8. PubMed ID: 19119449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy.
    Patil CS; Singh VP; Singh S; Kulkarni SK
    Pharmacology; 2004 Nov; 72(3):190-5. PubMed ID: 15452368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil.
    Patil CS; Singh VP; Kulkarni SK
    Inflammopharmacology; 2005; 13(5-6):467-78. PubMed ID: 16280099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rewarding properties of sildenafil citrate in mice: role of the nitric oxide-cyclic GMP pathway.
    Tahsili-Fahadan P; Yahyavi-Firouz-Abadi N; Orandi AH; Esmaeili B; Basseda Z; Dehpour AR
    Psychopharmacology (Berl); 2006 Apr; 185(2):201-7. PubMed ID: 16425058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of l -arginine/nitric oxide/cyclic GMP/K ATP channel signaling pathway and opioid receptors in the antinociceptive effect of rutin in mice.
    Fayazzadeh S; Fakhri S; Abbaszadeh F; Farzaei MH
    Behav Pharmacol; 2024 Oct; 35(7):399-407. PubMed ID: 39230435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test.
    Ambriz-Tututi M; Velázquez-Zamora DA; Urquiza-Marín H; Granados-Soto V
    Eur J Pharmacol; 2005 Apr; 512(2-3):121-7. PubMed ID: 15840396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester.
    Devan BD; Pistell PJ; Daffin LW; Nelson CM; Duffy KB; Bowker JL; Bharati IS; Sierra-Mercado D; Spangler EL; Ingram DK
    Eur J Pharmacol; 2007 Jun; 563(1-3):134-40. PubMed ID: 17362916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition.
    Devan BD; Bowker JL; Duffy KB; Bharati IS; Jimenez M; Sierra-Mercado D; Nelson CM; Spangler EL; Ingram DK
    Psychopharmacology (Berl); 2006 Jan; 183(4):439-45. PubMed ID: 16320087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway.
    Amarante LH; Duarte ID
    Eur J Pharmacol; 2002 Nov; 454(1):19-23. PubMed ID: 12409000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.